Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Randomized clinical trial of Appendicitis Inflammatory Response score-based management of patients with suspected appendicitis.

Andersson M, Kolodziej B, Andersson RE; STRAPPSCORE Study Group.

Br J Surg. 2017 Oct;104(11):1451-1461. doi: 10.1002/bjs.10637. Epub 2017 Jul 21.

PMID:
28730753
2.

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.

Hedlund PO, Johansson R, Damber JE, Hagerman I, Henriksson P, Iversen P, Klarskov P, Mogensen P, Rasmussen F, Varenhorst E; SPCG-5 STUDY GROUP.

Scand J Urol Nephrol. 2011 Nov;45(5):346-53. doi: 10.3109/00365599.2011.585820. Epub 2011 May 31.

PMID:
21627403
3.

Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.

Fransson P, Lund JA, Damber JE, Klepp O, Wiklund F, Fosså S, Widmark A; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3.

Lancet Oncol. 2009 Apr;10(4):370-80. doi: 10.1016/S1470-2045(09)70027-0. Epub 2009 Mar 13.

PMID:
19286422
4.

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3.

Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Epub 2008 Dec 16. Erratum in: Lancet. 2009 Apr 4;373(9670):1174.

5.

Reliability of death certificates in prostate cancer patients.

Fall K, Strömberg F, Rosell J, Andrèn O, Varenhorst E; South-East Region Prostate Cancer Group.

Scand J Urol Nephrol. 2008;42(4):352-7. doi: 10.1080/00365590802078583.

PMID:
18609293
6.

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.

Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J; SPCG-5 Study Group.

Scand J Urol Nephrol. 2008;42(3):220-9. doi: 10.1080/00365590801943274.

PMID:
18432528

Supplemental Content

Loading ...
Support Center